Press Release: FDA approves Novartis Cosentyx(R) -2-

Novartis is a focused innovative medicines company. Every day, we work to reimagine medicine to improve and extend people's lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide.

Reimagine medicine with us: Visit us at https://www.novartis.com and connect with us on LinkedIn https://www.linkedin.com/company/novartis, Facebook https://www.facebook.com/novartis/, X/Twitter https://twitter.com/Novartis and Instagram https://www.instagram.com/novartis/?hl=de.

References

1. Cosentyx Prescribing Information. East Hanover, NJ: Novartis

Pharmaceuticals Corp; October 2023.

2. Kimball AB, Jemec GBE, Alavi A, et al. Secukinumab in moderate to severe

hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and 52 results

of two identical, double-blind, placebo-controlled, phase 3 randomised

trials. Lancet. 2023; published online Feb 3. Available at:

https://doi.org/10.1016/S0140-6736(23)00022-3 [Last accessed: February

2023].

3. MedLine Plus. Hidradenitis suppurativa [online]. Available at:

https://medlineplus.gov/genetics/condition/hidradenitis-suppurativa/

https://medlineplus.gov/genetics/condition/hidradenitis-suppurativa/

[Last accessed: March 2022].

4. Sabat R, Jemec GBE, Matusiak L, et al. Hidradenitis suppurativa. Nat Rev

Dis Primers 2020;6:18. doi: 10.1038/s41572-020-0149-1

5. Kokolakis G, Wolk K, Schneider-Burrus S, et al. Delayed Diagnosis of

Hidradenitis Suppurativa and Its Effect on Patients and Healthcare

System. Dermatology. 2020;236:421-430.

6. Kimball AB, Okun MM, Williams DA, et al. Two phase 3 trials of adalimumab

for hidradenitis suppurativa. N Engl J Med. 2016;375:422-434.

7. Martora F, Megna M, Battista T, et al. Adalimumab, Ustekinumab, and

Secukinumab in the Management of Hidradenitis Suppurativa: A Review of

the Real-Life Experience. Clin Cosmet Investig Dermatol. 2023;16:135-148.

Published 2023 Jan 19. doi:10.2147/CCID.S391356 4.

8. Kimball AB, Jemec GBE, Alavi A, et al. Efficacy and Safety of Secukinumab

in Patients with Moderate to Severe Hidradenitis Suppurativa from the

Phase 3 SUNSHINE and SUNRISE Trials. Poster presented at American Academy

of Dermatology (AAD) 2023 Annual Meeting; March 17-21, 2023, New Orleans,

LA.

9. Girolomoni G, Mrowietz U and Paul C. Psoriasis: rationale for targeting

interleukin-17. Br J Dermatol. 2012;167:717-24.

10. McGonagle DG, McInnes IB, Kirkham BW, et al. The role of IL-17A in axial

spondyloarthritis and psoriatic arthritis: recent advances and

controversies. Annals Rheum Dis. 2019;78:1167-1178.

11. Baraliakos X, Braun J, Deodhar A, et al. Long-term efficacy and safety of

secukinumab 150 mg in ankylosing spondylitis: 5-year results from the

phase III MEASURE 1 extension study. RMD Open. 2019;5:e001005.

12. Bissonnette R, Luger T, Thaçi D, et al. Secukinumab demonstrates

high sustained efficacy and a favourable safety profile in patients with

moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE

Extension Study). J Eur Acad Dermatol Venereol. 2018;32:1507-1514.

13. Mease PJ, Kavanaugh A, Reimold A, et al. Secukinumab Provides Sustained

Improvements in the Signs and Symptoms of Psoriatic Arthritis: Final

5-year Results from the Phase 3 FUTURE 1 Study. ACR Open Rheumatol.

2020;2:18-25.

14. Data on file. CAIN457F2310 (MEASURE 1 and 2): Pooled Safety Data.

Novartis Pharmaceuticals Corp; July 23, 2018.

15. Data on file. CAIN457F2310 and CAIN457F2305 summary of 5-year clinical

safety in (ankylosing spondylitis). Novartis Pharmaceuticals Corp; May

2019.

16. Data on file. CAIN457F2312 Data Analysis Report. Novartis Pharmaceuticals

Corp; November 2008.

17. McInnes IB, Mease PJ, Kirkham B, et al. Secukinumab, a human

anti-interleukin-17A monoclonal antibody, in patients with psoriatic

arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled,

phase 3 trial. Lancet 2015;386:1137-46.

18. Data on file. COSENTYX Access. Novartis Pharmaceuticals Corp; January

2023.

19. Novartis AG. 2021. Novartis Cosentyx(R) receives FDA approval for the

treatment of children and adolescents with enthesitis-related arthritis

and psoriatic arthritis. [Press release]. Available

at: https://www.novartis.com/news/media-releases/novartis-cosentyx-receiv

es-fda-approval-treatment-children-and-adolescents-enthesitis-related-art

hritis-and-psoriatic-arthritis [Last accessed: February 2023].

20. Novartis Europharm Limited. Cosentyx(R) (secukinumab): Summary of Product

Characteristics. Available

at: https://www.ema.europa.eu/en/documents/product-information/cosentyx-e

par-product-information_en.pdf [Last accessed: July 2023].

# # #

Novartis Media Relations

E-mail: media.relations@novartis.com

Central North America

Richard Jarvis +41 79 584 2326 Julie Masow +1 862 579 8456

Anja von Treskow +41 79 392 9697 Michael Meo +1 862 274 5414

Anna Schäfers +41 79 801 7267 Marlena Abdinoor +1 617 335 9525

Switzerland

Satoshi Sugimoto +41 79 619 2035

Novartis Investor Relations

Central investor relations line: +41 61 324 7944

E-mail: investor.relations@novartis.com

Central North America

Samir Shah +41 61 324 7944 Sloan Simpson +1 862 345 4440

Nicole Zinsli-Somm +41 61 324 3809 Parag Mahanti +1 973 876 4912

Isabella Zinck +41 61 324 7188

(END) Dow Jones Newswires

October 31, 2023 16:50 ET (20:50 GMT)